PD-L1 Rabbit Monoclonal Antibody
Konjugasyon: Unconjugated
Recombinant rabbit monoclonal antibody
Uygulama
Reaktivite
Human
Gen Adı
PD-L1
Saklama
Aliquot and store at -20°C (valid for 12 months). Avoid freeze/thaw cycles.
Özet
| Ürün Adı | PD-L1 Rabbit Monoclonal Antibody |
| Açıklama | Recombinant rabbit monoclonal antibody |
| Konak | Rabbit |
| Reaktivite | Human |
| Konjugasyon | Unconjugated |
| Modifikasyon | Unmodified |
| İzotip | IgG |
| Klonalite | Monoclonal |
| Form | Liquid |
| Konsantrasyon | Unconjugated |
| Saklama | Aliquot and store at -20°C (valid for 12 months). Avoid freeze/thaw cycles. |
| Nakliye | Ice bags. |
| Tampon | Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% protective protein. Stable for 12 months from date of receipt. |
| Saflaştırma | Affinity Purification |
Antijen Bilgisi
| Gen Adı | PD-L1 |
| Alternatif İsimler | B7-H; B7H1; PDL1; PD-L1; hPD-L1; PDCD1L1; PDCD1LG1 |
| Gen Kimliği | 29126 |
| SwissProt Kimliği | Q9NZQ7 |
| İmmünojen | A synthetic peptide of human PD-L1 |
Uygulama
| Uygulama | WB,IHC,ICC/IF,FC,IP |
| Seyreltme Oranı | WB 1:500-1:2000,IHC 1:200-1:500,ICC/IF 1:100-1:200,FC 1:50-1:200,IP 1:20-1:50 |
| Moleküler Ağırlık | Calculated MW:33 kDa; Observed MW:40-50 kDa |
Araştırma Alanı
Arka Plan
| This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015] |
